


17W

32692

Customer Number

Patent
Case No.: 59090US004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: WIGHTMAN, PAUL D.
Application No.: 10/821319 Group Art Unit: 1644
Filed: April 9, 2004 Examiner: Unknown
Title: DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS USING
METAL-CONTAINING PARTICULATE SUPPORT MATERIALS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]	
I hereby certify that this correspondence is being:	
<input checked="" type="checkbox"/>	deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
<input type="checkbox"/>	transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 872-9306.
<u>June 16, 2005</u> Date	<u>Virginia Bergstrom</u> Signed By Virginia Bergstrom

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Copies of any cited foreign patents, foreign publications, non-patent literature documents, and any pending U.S. applications filed before June 30, 2003, are enclosed. Copies of any pending U.S. applications filed after June 30, 2003 that can be accessed on the USPTO's IFW system are not enclosed as per USPTO Waiver dated September 21, 2004. Copies of any U.S. patents and published U.S. patent applications are not enclosed.

Under 37 CFR § 1.97(e)(1), I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.

Under 37 CFR § 1.704(d), I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in

a counterpart application and that this communication was not received by any individual designated in 37 CFR § 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

A copy of the Search Report from a foreign counterpart application is enclosed.

It is believed that no fee is due; however, in the event a fee is required, please charge the fee to Deposit Account No. 13-3723.

Respectfully submitted,

June 15, 2005
Date

By: Ted K. Ringsred
Ted K. Ringsred, Reg. No.: 35,658
Telephone No.: (651) 736-5839

Office of Intellectual Property Counsel
3M Innovative Properties Company
Facsimile No.: 651-736-3833

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 1 of 1

U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US- 6,479,146 B1	11-12-2002	Caruso et al.	
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			
	A11	US-			

Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B1						
	B2						
	B3						
	B4						
	B5						
	B6						
	B7						

OTHER DOCUMENTS

Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation (Check if yes)
	C1	Hemmi et al., "Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway", <u>Nature Immunolo.</u> , February 2002, Vol. 3, No. 2, pp 196-200	
	C2		
	C3		

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement)